Cholesterol Decoded: What Your Lipid Panel Really Means

"Your cholesterol is a bit high." If you've heard this from your GP, you've likely been told to eat less saturated fat and come back in six months. But this oversimplification misses the real story. Modern cardiovascular research has moved far beyond total cholesterol, and understanding your full lipid panel could be the difference between early intervention and a preventable cardiac event.

Beyond Total Cholesterol

Total cholesterol is the sum of LDL-C, HDL-C, and VLDL-C. On its own, it's a poor predictor of cardiovascular risk. You can have a "normal" total cholesterol and still be at significant risk — or have elevated total cholesterol and be perfectly healthy (particularly if your HDL is high). The devil is in the details.

LDL Cholesterol: Not All Created Equal

LDL-C (low-density lipoprotein cholesterol) has long been labelled the "bad" cholesterol. While it's true that LDL drives atherosclerosis, the standard LDL-C measurement captures the amount of cholesterol within LDL particles — not the number of particles. This matters because someone with many small, dense LDL particles (pattern B) may have a "normal" LDL-C but significantly higher risk than someone with fewer, larger particles (pattern A) carrying the same cholesterol load.

ApoB: The Superior Marker

Apolipoprotein B (ApoB) measures the total number of atherogenic lipoprotein particles — including LDL, VLDL, and Lp(a). Each atherogenic particle carries exactly one ApoB molecule, making it a direct count of risk-driving particles. The European Atherosclerosis Society now recommends ApoB as the primary target for cardiovascular risk management.

Optimal ApoB for a healthy individual is below 0.9 g/L (standard range), but longevity-focused clinicians target below 0.7 g/L. For those with existing cardiovascular disease, below 0.65 g/L is recommended.

HDL Cholesterol: Higher Isn't Always Better

HDL-C (high-density lipoprotein cholesterol) has been called the "good" cholesterol because it participates in reverse cholesterol transport — carrying cholesterol back to the liver for disposal. However, recent research has complicated this picture. Very high HDL (> 2.3 mmol/L) may actually be associated with increased cardiovascular risk, possibly due to dysfunctional HDL particles. The optimal range appears to be 1.2–1.8 mmol/L.

Triglycerides: The Metabolic Indicator

Triglycerides are a type of fat in the blood, strongly influenced by diet (particularly carbohydrates and alcohol). Elevated triglycerides (> 1.7 mmol/L) are a hallmark of metabolic syndrome and insulin resistance. Optimal is below 1.0 mmol/L. The triglyceride-to-HDL ratio is also a useful proxy for insulin resistance — a ratio above 1.5 (in mmol/L) warrants investigation.

Lp(a): The Genetic Wildcard

Lipoprotein(a) is a genetically determined lipoprotein that is one of the strongest independent risk factors for cardiovascular disease. Unlike other lipid markers, Lp(a) is largely unaffected by diet or exercise — your levels are approximately 90% determined by genetics. Elevated Lp(a) (> 75 nmol/L) increases the risk of heart attack, stroke, and aortic valve stenosis.

Critically, Lp(a) is not routinely tested. You need to request it specifically, and it only needs to be measured once in your lifetime (since it's genetically fixed).

Key Ratios Worth Knowing

• Total cholesterol / HDL-C ratio — Optimal is below 3.5. Above 5.0 indicates elevated risk.
• Triglycerides / HDL-C ratio — A proxy for insulin resistance. Keep below 1.5 (mmol/L).
• ApoB / ApoA1 ratio — Captures the balance between atherogenic and protective particles. Optimal is below 0.7.

What to Do About It

If your lipid panel reveals concerning values, the first-line intervention is always lifestyle: reduce refined carbohydrates and sugar, increase omega-3 intake (fatty fish, walnuts, flaxseed), exercise regularly, and maintain a healthy weight. For those with persistently elevated ApoB or familial hypercholesterolaemia, statin therapy remains one of the most evidence-backed interventions in modern medicine.

References

1. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
2. Nordestgaard BG, et al. Lipoprotein(a) as a cardiovascular risk factor. Eur Heart J. 2010;31(23):2844-2853. doi:10.1093/eurheartj/ehq386
3. Madsen CM, et al. Extreme high HDL cholesterol is paradoxically associated with high mortality. Eur Heart J. 2017;38(32):2478-2486. doi:10.1093/eurheartj/ehx163
4. Sniderman AD, et al. Apolipoprotein B Particles and Cardiovascular Disease. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780